If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.50
Bid: 1,700.00
Ask: 1,800.00
Change: 0.00 (0.00%)
Spread: 100.00 (5.882%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,799.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK Annual Report 2023 on Form 20-F

5 Mar 2024 17:24

RNS Number : 7075F
GSK PLC
05 March 2024
 

Issued: 5 March 2024, London UK

 

GSK plc 2023 Annual Report on Form 20-F

 

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GSK plc ("GSK") announces that on 5 March 2024 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2023. GSK's 2023 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

A hard copy version of the GSK 2023 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2024.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2023, free of charge, by either:

 

(i)

writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on +44 (0)371 384 2991 (please use the area code if calling from outside the UK);

 

(ii)

writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 877 353 1154 (US toll free) or +1 651 453 2128 (outside the US); or

 

(iii)

contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

Victoria WhyteCompany Secretary5 March 2024

 

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSQKPBBOBKDKNK
Date   Source Headline
26th Sep 20225:09 pmRNSDirector/PDMR Shareholding
26th Sep 20227:00 amRNSGSK Chief Financial Officer succession
22nd Sep 20222:00 pmRNSUS FDA ODAC review of Zejula Phase III NOVA trial
22nd Sep 20227:00 amRNSGSK and Spero Therapeutics licence for tebipenem
21st Sep 202211:22 amRNSDirector/PDMR Shareholding
13th Sep 20229:11 amRNSDirector/PDMR Shareholding
9th Sep 20229:11 amRNSPublication of Base Prospectus
8th Sep 202212:58 pmRNSDirector/PDMR Shareholding
6th Sep 20221:00 pmRNSGSK provides update on FDA review of daprodustat
1st Sep 202211:48 amRNSTotal Voting Rights
24th Aug 20227:00 amRNSGSK Board changes
22nd Aug 20224:53 pmRNSDirector/PDMR Shareholding
17th Aug 20227:00 amRNSFDA New Drug Application File Acceptance for MMB
17th Aug 20227:00 amRNSStatement: Zantac (ranitidine) litigation update
16th Aug 20227:06 amRNSGSK completes acquisition of Affinivax, Inc.
12th Aug 20227:00 amRNSStatement: Zantac (ranitidine) litigation
11th Aug 202211:51 amRNSDirector/PDMR Shareholding
10th Aug 20224:57 pmRNSDirector/PDMR Shareholding
1st Aug 20226:10 pmRNSTotal Voting Rights
1st Aug 20221:43 pmRNSDirector/PDMR Shareholding
29th Jul 20222:00 pmRNSDirector/PDMR Shareholding
29th Jul 202210:00 amRNSGSK Board change
28th Jul 20221:01 pmRNSDirector/PDMR Shareholding
27th Jul 20227:00 amRNS2nd Quarter Results
26th Jul 20225:35 pmRNSHolding(s) in Company
22nd Jul 20224:45 pmRNSHolding(s) in Company
22nd Jul 20224:17 pmRNSBoard and Committee Changes
19th Jul 20227:00 amRNSCompletion of GSK Share Consolidation
18th Jul 20226:00 pmRNSHolding(s) in Company
18th Jul 20227:00 amRNSHaleon demerger completion and share consolidation
12th Jul 20229:48 amRNSDirector/PDMR Shareholding
11th Jul 20225:30 pmRNSGSK
8th Jul 20226:04 pmRNSDirector/PDMR Shareholding
8th Jul 20225:30 pmRNSDirector/PDMR Shareholding
8th Jul 20223:53 pmRNSDirector/PDMR Shareholding
8th Jul 20223:33 pmRNSDirector/PDMR Shareholding
8th Jul 20223:10 pmRNSDirector/PDMR Shareholding
6th Jul 20224:30 pmRNSResult of General Meeting
6th Jul 202210:11 amRNSDirector/PDMR Shareholding
5th Jul 202212:43 pmRNSGSK disclose discontinued operations from Q2 2022
5th Jul 20229:45 amRNSDirector/PDMR Shareholding
5th Jul 20229:30 amRNSDirector/PDMR Shareholding
1st Jul 20223:27 pmRNSTotal Voting Rights
1st Jul 20222:45 pmRNSGSK completes acquisition of Sierra Oncology
28th Jun 20225:56 pmRNSDirector/PDMR Shareholding
28th Jun 20227:00 amRNSGSK files Shingrix 18+ at risk indication in Japan
27th Jun 20224:08 pmRNSDirector/PDMR Shareholding
24th Jun 20223:44 pmRNSDirector/PDMR Shareholding
16th Jun 202210:58 amRNSDirector/PDMR Shareholding
10th Jun 20227:00 amRNSPositive phase III data for GSK’s RSV OA vaccine

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.